Oral GLP-1 agonist Orforglipron – what do we know so far?

Posted by optimizer_jenna in Research & News - 1 points, 0 comments.

com/peptides/orforglipron) and tbh it caught my eye because it’s an oral GLP-1 agonist, which could skip the injections we see with semaglutide. The description says it’s a small molecule with decent bioavailability and early trials showing 8‑14 % weight loss, but also notes nausea and GI stuff that are dose‑dependent. As someone who’s still sorting out what’s hype vs real in the longevity space, I wonder how the long‑term safety looks compared to the injectable versions, especially since the half‑life is 25‑60 hours.

Has anyone here followed the newer press releases or seen any human data beyond the phase 2 numbers? Would love to hear what you think about the trade‑off between convenience and potential side effects.

Community discussion - research and educational context only. Not medical advice.